Status:
RECRUITING
Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma
Lead Sponsor:
Instituto Nacional de Cancer, Brazil
Conditions:
Mucositis Oral
Eligibility:
All Genders
Up to 19 years
Phase:
NA
Brief Summary
This study aims to evaluate the photobiomodulation therapy (PBMT) for the prevention of oral mucositis in osteosarcoma patients submitted to high doses of methotrexate, through two different protocols...
Detailed Description
This is a phase 3, randomized study, with patients diagnosed with osteosarcoma, enrolled at national cancer institute in Brazil (INCA), candidates for the Glato protocol (chemotherapy with doxorubicin...
Eligibility Criteria
Inclusion
- Patients enrolled at INCA diagnosed with OS (ICD10-C41), aged 0 to 19 years;
- Patients with indication for Glato chemotherapy protocol, which will use high doses of MTX (HD-MTX (\>1 g/m2).
- Patients who, after receiving information and instructions, signed the patient's informed consent/assent form, in accordance with Resolution 466/12 of the National Health Council.
Exclusion
- \- Patients who do not agree with the proposed treatment.
Key Trial Info
Start Date :
October 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2025
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT06217224
Start Date
October 17 2022
End Date
July 30 2025
Last Update
January 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Rio de Janeiro, Brazil, 20230-130